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Background. Selective serotonin reuptake inhibitor (SSRI) therapy complicates up to 10% of pregnancies. During therapy,
SSRIs exert pleiotropic antidepressant, anorexigenic, and neurotrophic eﬀects. Intrauterine SSRI exposure has been modeled
by neonatal administration to developmentally immature rodents, and it has paradoxically elicited features of adult depression.
We hypothesized neonatal SSRI exposure likewise programs a rebound hypermetabolic state in adult mice. Methods. C57BL/6
pups were randomized to saline or sertraline (5mg/kg/d) from P1–P14. Because estrogen increases tryptophan hydroxylase
2 (TPH2) expression, a subset of female mice underwent sham surgery or bilateral ovariectomy (OVX). Metabolic rate was
determined by indirect calorimetry. Results. In both male and female mice, neonatal SSRI exposure increased adult caloric intake
and metabolic rate. SSRI-exposed female mice had signiﬁcantly decreased adult weight with a relative increase in brain weight
and melatonin excretion, independent of ovarian status. Cerebral cortex TPH2 expression was increased in SSRI-exposed male
mice but decreased in OVX SSRI-exposed female mice. Conclusions. SSRI exposure during a critical neurodevelopmental window
increasesadultcaloricintakeandmetabolicrate.OvarianstatusmodulatedcentralTPH2expression,butnotadultenergybalance,
suggesting programmed neural connectivity or enhanced melatonin production may play a more important role in the post-SSRI
hypermetabolic syndrome.
1.Introduction
The prevalence of depression during pregnancy now exceeds
18%, and more than 13% of pregnancies were complicated
by antidepressant therapy in 2003, twice as many as in 1999
[1, 2]. The majority of this increase has come from a height-
ened utilization of selective serotonin reuptake inhibitors
(SSRIs) [2–6]. Among the SSRIs, sertraline remains the most
commonly prescribed antidepressant in America [2].
Recent studies have demonstrated detrimental eﬀects of
in utero SSRI exposure, including fetal growth restriction,
neonatal abstinence syndrome, and persistent pulmonary
hypertension [5, 7]. The eﬀects of third trimester exposure
are often felt to be transient in nature. However, Oberlander
and colleagues have demonstrated changes in hypothalamic,
cardiovascular, and nociceptive regulation up to 4 months
following delivery, and SSRI exposure has now been associ-
ated with increased autism risk [8–13].
Murine models of human neurodevelopment are well
established, with the ﬁrst fourteen postnatal days approx-
imating the third trimester of human development [14].
Exposure of male rats to the SSRI citalopram at the later
end of this critical window (P8–P21) decreases dorsal raphe
tryptophan hydroxylase (TPH) immunoreactivity and elic-
its behavioral changes consistent with depression [15].
Further studies on that model have identiﬁed SSRI-induced
disruptionsinneuralnetworksandupregulationofthenora-
drenergic locus ceruleus system [16, 17]. When reported,
outcomeshavebeenbluntedinfemalemiceandrats[16,17];
suggesting estrogen-stimulated TPH expression may provide
partial protection [18].2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
We sought to expand the assessment of SSRI-pro-
grammed phenotypes and determine the sex-speciﬁc eﬀects
of neonatal exposure to sertraline, the most commonly
prescribed antidepressant. Given the known anorexigenic
and sympathoinhibitory eﬀects of acute SSRI administration
[19–21], we speculated alterations in energy balance may
be a component of a potential “post-SSRI syndrome.” We
hypothesized that SSRI-exposed male and ovariectomized
female mice have decreased adult serotonergic tone that is
manifest by increased feed intake and basal metabolic rate.
2. Methods
2.1. Animal Model. Pregnant C57BL/6 mice (Jackson Lab-
oratory, Bar Harbor, ME) were allowed natural delivery
and within 12 hours of birth, each litter was adjusted to 6
pups, via culling or adding age-matched pups from other
dams. While C57BL/6 dams readily accept cross-fostered
pups [22, 23], a recent publication described alterations in
adult outcomeswhenentire litters were cross-fosteredat 48h
[23]. A vast majority of litters did not require any additional
pups, and the confounding eﬀects of cross-fostering were
minimized by randomization. Pups were then randomized
within each litter to either receive intraperitoneal saline
(10mL/kg/d) or sertraline (5mg/kg/d) on days P1–14. This
corresponds to a neurodevelopmental window similar to the
third trimester in human gestation. The dose utilized was
determined from the equation: murine dose = maternal oral
dose/maternal body surface area × murine body surface area
× oral bioavailability × placental transfer ratio. Utilizing
the equation of Meeh for murine body surface area [9.8 ×
(weighting)2/3][24],theaverageweightofmiceat14d(7g),
the equation of Du Bois for human body surface area [71.84
× (weight in kg)0.425× (height in cm)0.725][ 25], the average
weight and height of women in the third trimester (80kg,
162cm), 70% oral bioavailability and 29% placental transfer
[26], the equation simpliﬁes to murine dose = maternal dose
∗ 0.00039. Thus, to replicate typical low-dose therapy of
100mg/d, we utilized 0.039mg/d or ∼5.6mg/kg/d. To verify
the clinical relevance of this dosing regimen, plasma was
collected 2h or 12h after the ﬁnal dose of sertraline. Prior
to collection, pups were anesthetized with isoﬂurane (1%),
the liver was excised and 600–750 microliter of blood was
collected. Plasma was stored at −20◦C prior to analysis by
gas chromatography at NMS Labs (Willow Grove, PA).
Tofurtherassesstheprotectiveeﬀectofovarianfunction,
a subset of 5- to 6-month-old female mice underwent
bilateral ovariectomy (OVX) versus sham surgery (ovary
visualization without resection) via paravertebral approach
under isoﬂurane anesthesia. Analgesia was provided with
ﬂunixin meglumine (2.5mg/kg once or twice daily), as
well as 0.5% bupivacaine along the incisions. A minimum
of one month of surgical recovery was provided prior to
phenotyping. All surgeries and protocols were in accordance
with NIH guidelines and were approved by the Institutional
Animal Care and Use Committee at the University of Iowa.
All investigations were designed to reduce the numbers of
animals required and procedures were modiﬁed to lessen or
eliminate pain and distress.
2.2. In Vivo Phenotypes. Feed consumption and weight were
measured over a 14-day interval while mice received ad lib
standard rodent chow (4kcal/g, 6% of energy as fat; 7013;
Harlan Teklad, Madison, WI). Basal metabolic rate was then
assessedviaindirectcalorimetryinanairtightthermoneutral
chamber. Oxygen consumption (VO2) was calculated while
the mice were asleep, as previously described [27]. For male
mice, physiologic studies (performed at 5–7 months) were
followed by brain harvest under general anesthesia at 6–
9 months. The female mice that underwent ovariectomy
or sham surgery had delayed euthanasia (11-12 months).
During this delay, analysis of the in vivo phenotype data
led us to place them in a metabolic cage for determination
of 24h urinary melatonin excretion. Samples were stored
at −80 degrees until analysis in duplicate for melatonin
sulfate(ELISAkitRE54031,IBLTransatlantic).Sampleswith
no detectible melatonin sulfate (lower limit of detection
1ng/mL) were analyzed with a value of zero. There was one
such sample present in each of the 4 groups. Following these
studies, female mice were euthanized by organ harvest under
general anesthesia, and tissue weights were obtained.
2.3. Tryptophan Hydroxylase Expression. The brain was
quickly and bluntly segmented and stored in RNAlater until
puriﬁcation with RNeasy kits (Qiagen, Valencia, CA). Initial
coronal sectioning removed the olfactory bulbs anteriorly,
as well as the cerebellum and medulla posteriorly. The
remaining brain was then sectioned both superiorly and
laterally to obtain a sample labeled “cortex” including both
thecerebralcortexandpinealgland.Theremainingsegment,
labeled “midbrain” included the dorsal raphe nucleus as
well as the diencephalon (thalamus and hypothalamus).
Finer dissection was not completed to avoid loss of message
due to either passage of time or indiscriminate removal of
grossly indistinct regions. RNA was quantitated using a Nan-
oDrop ND-1000 spectrophotometer (Labtech International,
East Sussex, UK). Reverse-transcription reactions were per-
formed on 0.5µg total RNA with the addition of oligo dT,
dNTPs, DTT, RNasin, and Superscript III reverse transcrip-
tase (Invitrogen). Quantitative real-time RT-PCR (qPCR)
utilized the TaqMan reagent and instrumentation systems
(Applied Biosystems, Foster City, CA). Taqman gene expres-
sion assay primer/probe sets for mouse Tph1 (assay ID =
Mm00493794 m1; context sequence = CCGACCACCCTG-
GCTTCAAAGACAA), Tph2 (assay ID = Mm00557715 m1;
context sequence = TAGACTATTCCAGGAAAAACATGTC),
and GAPDH were purchased from Applied Biosystems
(Foster City, CA). Since the reaction eﬃciencies for the 3
assays are matched by design, we used the ΔΔCT method for
quantitation.
2.4. Data Analysis. All values other than TPH expression
data are presented as mean ± SEM. TPH expression is
presented as % control = 100 × 2(−ΔΔCT) with correspond-
ing error bars equal to 100 × 2(−ΔΔCT±pooledSE). Statistical
c o m p a r i s o n sw e r em a d eu s i n gt w o - w a yA N O V Aa n dt h e
Holm-Sidak method for multiple pair-wise comparisons.
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Figure 1: Neonatal SSRI exposure acutely decreased pup growth.
Pups were weighed immediately prior to daily administration
of 10mL/kg saline (white symbols) or 5mg/kg sertraline (gray
symbols) from P1 to P14. N = 34 control and 40 SSRI-exposed
pups. ∗P<0.05 bytwoway repeated measures ANOVA withHolm-
Sidak method for multiple pair-wise comparisons.
SSRI exposure and ovarian status, pairwise comparisons
were made by the Holm-Sidak method. Postmortem tissue
weights were compared by Student’s t-test. A value of P<
0.05 was considered signiﬁcant. All analyses were performed
using SigmaPlot 12 (Systat Software Inc.).
3. Results
3.1. Acute Sertraline Administration Decreases the Growth of
Neonatal Mice and Models Intrauterine Human Exposure.
Pup weights at the initiation of sertraline exposure (P1)
were similar (control 1.49 ± 0.02g, SSRI-exposed 1.46 ±
0.02g). Throughout the ﬁnal 9 days of injections (P6–
P14), sertraline-exposed mice had mild but statistically
signiﬁcant growth restriction (Figure 1, overall ANOVA P =
0.032, diﬀerence of means 0.26g). On the ﬁnal day of
exposure (14d), plasma levels 2h after injection were 71.8
± 1.3ng/mL (N = 6) and 12h after injection were 13.1
± 0.6ng/mL (N = 7). Based on these levels, there was a
half-life 4.1h, estimated peak concentration 101ng/mL, and
estimated trough concentration of 1.7ng/mL. Our projected
peak concentration approximates that seen in pregnancy
(99ng/mL based on 150mg/d dosing) [28], and our pro-
jectedtroughapproximatesumbilicalcordlevels(4.9ng/mL)
[26]. The mean plasma level in mice (24.8ng/mL) closely
approximates mean human levels measured in the general
population (20.4ng/mL) and in pregnant women (also
20.4ng/mL) [26, 29].
3.2. Neonatal SSRI Exposure Induces a Hypermetabolic State.
Body weight had normalized at the beginning of adult
phenotype assessment at 5–7 months (Figure 2(a)). At this
point, mice were separated into individual cages to quantify
feed intake. Sertraline exposure increased adult male and
femalecaloricintake(Figure 2(b),P = 0.004).Thisincreased
caloric intake was matched by an increased basal metabolic
rate (resting oxygen consumption) in both male and female
SSRI-exposed mice (Figure 3, P = 0.033). Upon necropsy,
SSRI-exposed female and male mice had decreased body
weight (Table 1, P = 0.021 and P = 0.048, resp.) with
increased relative brain weight seen in females (P = 0.017)
but not males (P = 0.56). Additional organ weights were not
obtained from male mice. Among female mice, there were
no signiﬁcant alterations in the absolute or relative weights
of the liver (P = 0.07), intraabdominal white adipose tissue
(P = 0.09), or interscapular brown adipose tissue (P =
0.85), although body composition tended to be leaner in the
growth-restricted SSRI-exposed mice (Table 1).
3.3. Neonatal Sertraline Exposure Increases Adult Trypto-
phan Hydroxylase Expression and Melatonin Excretion. In
order to assess central serotonergic tone, regional and
isoform-speciﬁc TPH expression was determined. By qPCR
(Figure 4(a)),SSRI-exposedmalemicehadincreasedexpres-
sion of the major TPH isoform (TPH2) within the cerebral
cortex (2.8-fold increase, P = 0.048) and midbrain (2.5-
fold increase, P = 0.11). Among female mice, there was an
interaction between SSRI exposure and OVX (P = 0.017),
with signiﬁcantly decreased TPH2 expression in OVX SSRI-
exposed mice cortex (P = 0.027). Brain TPH1 mRNA
expression was not altered by SSRI exposure or ovarian
status (Figure 4(b)). Overall, TPH2 mRNA expression was
enriched 143-fold in the midbrain (ΔCT: 4.2 ± 0.3)
versus the cortex (ΔCT: 11.3 ± 0.2), while TPH1 mRNA
expression was increased 2-fold in the cortex (ΔCT: 10.8 ±
0.1) over the midbrain (ΔCT: 11.9 ± 0.1). Because a vast
majority of excreted serotonin metabolites originate from
systemic rather central sources, we chose to measure urinary
excretion of the stable melatonin metabolite, melatonin
sulfate [30]. Unlike serotonin produced within the dorsal
raphe, melatonin produced within the pineal gland readily
enters the systemic circulation such that urinary excretion
allows for noninvasive approximation of central production.
Independent of ovarian status, neonatal SSRI exposure
increased urinary melatonin sulfate excretion (Figure 5, P =
0.034).
4. Discussion
Over the past decade, a growing percentage of infants have
been exposed to maternal antidepressant therapy without
long-term outcome data. Animal models have been devel-
opedtoﬁllthisvoid.Advantagesofmurinemodelsofhuman
exposures include a shortened lifespan allowing life-course
assessment and the availability of isogenic inbred strains. To
capitalize on these advantages, a well-timed clinically rele-
vant environmental exposure must be introduced during a
critical window of developmental susceptibility. Intrauterine
SSRI exposure induces cardiac malformations in mice that4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 2: Neonatal SSRI exposure increases adult caloric intake. Intake of standard rodent chow was recorded over a 2 week interval and
compared between control mice that received 10mL/kg/d saline (white bars) and SSRI-exposed mice that received 5mg/kg/d sertraline (gray
bars) from P1 to P14. N = 27 control female (16 litters), 24 SSRI-exposed female (14 litters), 14 control male (9 litters), 12 SSRI-exposed
male (10 litters); ∗P = 0.004 versus control by ANOVA.
Table 1: From postnatal day 1 to 14, mice received injections of saline (control) or the SSRI sertraline. After obtaining adult phenotypes,
tissue weights were obtained from 11- to 12-month-old female and 6- to 9-month-old male mice. ∗P<0.05 versus control by Student’s
t-test
Female Female Male Male
Control SSRI Control SSRI
N 15 14 8 10
Body Weight (g) 35.3 ± 1.6 29.6 ± 1.7 ∗ 39.7 ± 2.1 35.0 ± 1.0∗
Brain (mg) 457 ± 4 458 ± 4 421 ± 12 406 ± 8
(mg/g) 13.3 ± 0.6 16.1 ± 0.9 ∗ 10.9 ± 0.7 11.3 ± 0.4
Liver (mg) 1251 ± 103 1241 ± 70
(mg/g) 37 ± 34 2 ± 2
White adipose (mg) 2688 ± 308 1761 ± 396
(mg/g) 73 ± 65 3 ± 9
Brown adipose (mg) 127 ± 12 109 ± 12
(mg/g) 3.6 ± 0.3 3.6 ± 0.3
are reminiscent of the congenital cardiac defects seen with
intrauterineSSRIexposureinhumans[31–34].However,the
third trimester of human neurodevelopment is best modeled
in neonatal mice and rats. In rats, neonatal SSRI exposure
decreases synaptogenesis and elicits features consistent with
depression [15–17]. This post-SSRI syndrome appeared to
have a sexually dimorphic presentation with male mice
aﬀected more than females. Our well-powered investigations
clarify and extend these studies in demonstrating an SSRI-
programmed hypermetabolic state in both male and female
mice. Our data further demonstrate that while ovarian func-
tion modulates serotonergic tone, females are not sheltered
from the eﬀects of neonatal SSRI exposure.
Our dosing regimen (5mg/kg once daily) was designed
to replicate intrauterine exposure to maternal doses of only
100mgoncedaily,anditmatchesthelowestexposureusedin
analogous preclinical studies [35]. Based on studies showing
dose-dependent growth inhibition by sertraline [35], it is
possible higher exposures may elicit greater programming
eﬀects. Consistent with the results seen in rats, neonatal mice
have faster sertraline elimination (half-life 4h) than young
women (half-life 32h) [36, 37]. We utilized a typical once
dailydosingregimenthatledtoslightlyexaggeratedpeakand
trough ﬂuctuations. Further studies with a more frequent
dosing interval are needed to determine the programming
eﬀects of the absolute exposure versus the pattern of expo-
sure and withdrawal. Notably, intrauterine SSRI exposure-
associated neonatal abstinence syndrome appears to increase
theriskforpersistentsocial-behavioralabnormalities[5,38].
The increased feed intake we identiﬁed in SSRI exposed
adult mice contrasts with the anorexigenic eﬀect of acute
SSRI therapy [39, 40]. This is consistent with the develop-
mental origins “predictive adaptive responses” theory or the
broader developmental biology principle of phenotypic plas-
ticity [41]. Both ﬁelds agree that when normal physiologic
processes are perturbed by environmental exposures, the
organism adapts to restore homeostatic balance. However,
if the exposure ceases after this window of developmentalJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
0
0.5
1
1.5
2
2.5
3
3.5
Female  Male
O
x
y
g
e
n
 
c
o
n
s
u
m
p
t
i
o
n
 
(
m
L
/
m
i
n
/
g
)
∗
∗
Figure 3: Neonatal SSRI exposure increases adult basal metabolic
rates. Control (white bars) and SSRI-exposed mice (gray bars) were
placed in a thermoneutral environment and oxygen consumption
rates were measured during sleep (nadir in oxygen consumption).
N = 27 control female (17 litters), 24 SSRI-exposed female (15
litters),12controlmale(9litters),13SSRI-exposedmale(10litters);
∗P = 0.033 versus control by ANOVA.
plasticity closes,theadaptive response maybeﬁxed andexert
maladaptive eﬀects. The remainder of our investigations
sought to unravel the developmental origins of this SSRI-
induced adult hyperphagia.
Intriguingly, despite the increased caloric intake of
SSRI-exposed mice, body weight was either maintained or
decreased compared to saline-exposed controls. While the
concomitant increase in metabolic rate seen in SSRI-exposed
mice may be explanatory, further studies are necessary to
deﬁne whether the increased feed intake is a primary alter-
ation or a reaction to the increased energy utilization. The
diminished weight gain seen in SSRI-exposed mice between
baseline assessment and necropsy is consistent with their
hypermetabolic state. A cause-eﬀect relationship would be
strengthened through investigation of alternative explana-
tions, including the potential that neonatal SSRI expo-
sure increases the stress/catabolic response to phenotypic
assessment or the stress/hyperactivity response to isolation
within the home cage. The SSRI-induced hypermetabolic
state (increased resting expenditure) is itself a novel ﬁnding
with a number of potential etiologies. Notably, the lean
body habitus induced by neonatal SSRI exposure may both
account for the increase in metabolic rate (as indexed by
body weight) and be a manifestation of the hypermetabolic
state. Among factors known to increase metabolic rate,
activation of the adrenosympathetic or thyroid axes merit
further consideration, especially in light of observational
studies that have found an association between intrauterine
SSRI exposure and postnatal hypothalamic alterations [13].
To further explore the molecular etiology for the persis-
tent hypermetabolic state, we assessed cortical and midbrain
TPH expression. SSRI-exposed male mice had a dramatic
increase in expression of TPH2. While statistical analysis
only reached signiﬁcance in the cortex, similar eﬀects were
apparent in the midbrain. Consistent with studies in humans
[42], we detected lower TPH2 expression in the cerebral
cortex then in the midbrain section containing the dorsal
raphe nucleus. Although there is currently no evidence
this cortical expression substantially contributes to central
serotonin synthesis, increased cortical TPH expression and
activity has been associated with suicide in humans and
altered stress hormone levels in rats [43, 44]. Further studies
with region-speciﬁc TPH2 overexpression or inactivation
willbeneededtoassesstheeﬀectsofcorticalTPH2oncentral
serotoninlevelsandbehavioralphenotypes. Basedonstudies
showing dose-dependent inhibition of TPH by SSRIs, it is
also possible higher or more frequent exposures would also
have greater eﬀects on adult TPH expression and metabolic
parameters.
Our results in male mice are in stark contrast with
the reduced TPH immunoreactivity seen in the rat dorsal
raphe nucleus following citalopram administration from
P8–P21. Potential explanations for the discrepancy include:
diﬀerences in mRNA versus protein expression (e.g., pres-
ence of RNA interference or instability), SSRI-speciﬁc or
species-speciﬁc eﬀects, and vastly diﬀerent windows of
exposure. Our data showing increased TPH2 after sertraline
exposure is consistent with the increase in TPH mRNA
and protein expression seen during sertraline or ﬂuoxetine
administration to rats [45]. Although parallel changes in
mRNA and protein have been reported following sertraline
exposure, it is possible that TPH1 and TPH2 are regulated
at both transcriptional and translational levels. Recently
developed TPH1 and TPH2 antibodies may permit analysis
of isoform-speciﬁc expression with future cohorts of mice
[46]. Interestingly, during acute citalopram administration,
there is a decrease in TPH2 mRNA that does not translate to
a change in protein levels [47], highlighting the importance
of SSRI-speciﬁc research.
In our investigations, there was a clear impact of sex
and a lesser eﬀect of ovarian status on SSRI-induced TPH2
expression, suggesting the programmed alterations in TPH2
expression were likely established before pubertal develop-
ment. Notably, we previously demonstrated male mice have
a delayed neonatal window of developmental susceptibility
[27], consistent with the female advantage seen following
premature delivery [48]. It is possible an earlier window of
exposure would be necessary to induce similar programming
eﬀects in females.
Our study is one of the ﬁrst investigations to report long-
term outcomes in SSRI-exposed female as well as male mice.
OtherthanTPH2mRNAexpressionandadultbrainweights,
very similar phenotypes were seen in male and female mice,
in contrast to the sex-speciﬁc diﬀerences often reported in
undernutrition or reduced uterine perfusion models of
metabolic and cardiovascular programming [27, 49, 50].
Because the gene expression studies were not completed at
the same age in male and female mice and the male mice did
not undergo survival surgery, direct comparison of male and
female TPH expression patterns are diﬃcult. Regardless, the
lack of correlation between central TPH2 expression and the
hypermetabolic aspect of the post-SSRI syndrome led us to
explore alternative etiologies.6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
0
100
200
300
400
500
Male OVX OVX Female Male Female
T
P
H
2
 
e
x
p
r
e
s
s
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
∗
∗
Midbrain Cerebral cortex
(a)
0
50
100
150
200
Male Male OVX OVX Female Female
T
P
H
1
 
e
x
p
r
e
s
s
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
Midbrain Cerebral cortex
(b)
Figure 4:CerebralcortexexpressionofTPH2mRNAisincreasedinSSRI-exposedmalemice.PCRwasperformedonmidbrainandcerebral
cortex homogenates obtained from control and SSRI-exposed mice (gray bars). Expression of the two tryptophan hydroxylase isoforms
(TPH2 and TPH1) was normalized by GAPDH and ΔΔCT values were calculated to determine relative mRNA abundance. N = 5–10 mice
from 5–8 litters per group; ∗P<0.05 versus control by ANOVA with the Holm-Sidak method for multiple comparisons.
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Figure 5: Urinary excretion of the major melatonin metabolite is
increased by neonatal SSRI exposure independent of ovarian status.
Mice were placed in metabolic cages for 24 hours and urinary
excretion of melatonin sulfate was quantiﬁed by ELISA for samples
from control (white bars) and SSRI-exposed mice (gray bars) that
had undergone sham surgery or bilateral ovariectomy at least one
monthprior tocollection. N = 5–9 micefrom5–7 litterspergroup;
∗P = 0.034 versus control by ANOVA, P = 0.23 for ovariectomy
versus sham surgery.
Prior studies suggested TPH1 is expressed in the cortex
during neurodevelopment and we hypothesized SSRI expo-
sure might trigger a persistence of this immature expression
pattern [51]. While ours conﬁrmed an increased expression
in the cortex and pineal sample relative to that in the
midbrain, there was no signiﬁcant programming eﬀect seen.
Further studies are needed focused on pineal gland mRNA
and protein expression of enzymes within the melatonin
synthetic pathway.
We were interested in melatonin for a number of reasons.
Melatoninandserotoninsharemetabolicpathwaysincluding
tryptophan hydroxylase conversion of tryptophan to the
common precursor, 5-hydroxytryptophan. Exogenous mela-
tonin has demonstrated eﬃcacy in animal models of obesity
with weight loss attributed to an increase in metabolic
rate, potentially through noradrenaline sensitization or
increased mitochondrial respiration [52–54]. The increased
melatonin sulfate excretion seen in female mice following
neonatalSSRIexposuremaythuscontributetotheassociated
hypermetabolic state. Because caloric intake, metabolic rate
and TPH1 expression did not show sex-speciﬁc diﬀerences,
additional male mice were not generated for the determi-
nation of urinary melatonin excretion. Notably, TPH is not
the rate-limiting enzyme in melatonin production. Further
studies, including microdialysis, are needed to deﬁne the
circadian pattern of serotonin and melatonin production
within discrete brain regions. Likewise, serotonin receptor
antagonists and/or pinealectomy would help disentangle
the importance of these signaling pathways in programmed
mice.
In conclusion, the exposure of neonatal mice to the most
commonly prescribed SSRI led to a post-SSRI syndrome
associated with a hypermetabolic state, an upregulation of
TPH expression in male mice, and increased melatonin
excretion in female mice. The anorexigenic eﬀects of sero-
tonin and melatonin, as well as the lack of obesity in male
and female mice, suggest the hyperphagia is not a primary
phenotype, and it may be a compensation for the increased
metabolic rate. In addition to translational mechanistic
studies, clinical assessments are critically needed to assess the
metabolicandneuroendocrinestatusofinfantsinadvertently
exposed to maternal SSRI therapy.
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